FENCNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

FENNEC PHARMACEUTICALS INC.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026

$10.27+0.29 (+2.91%)

Close on Oct 19, 2026

Market cap: $374.14M
P/E (TTM): –
Dividend yield: –

FENNEC PHARMACEUTICALS INC. balance sheet

Annual Quarterly

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31	FY 2018 2018-12-31	FY 2017 2017-12-31	FY 2016 2016-12-31	FY 2015 2015-12-31	FY 2014 2014-12-31	FY 2013 2013-12-31	FY 2012 2012-12-31	FY 2011 2011-12-31	FY 2010 2010-12-31	FY 2009 2009-12-31	FY 2008 2008-12-31	FY 2007 2007-12-31	FY 2006 2006-12-31
Cash & Equivalents	37	27	13	24	0.31	0.01	678	23	28	3.93	0.94	2.31	1.66	2.30	5.30	5.95	0.69	–	–	–
Cash & Short-Term Investments	37	27	13	24	0.31	0.01	678	23	28	3.93	0.94	2.31	1.66	2.30	5.30	5.95	0.69	–	–	–
Prepaid Expenses & Other	3.74	3.08	2.58	0.77	1.03	0.80	0.23	0.17	0.13	0.04	0.08	0.05	0.08	0.06	0.04	0.04	–	–	–	–
Other Current Assets	1.73	0.47	0.04	0.06	0.25	0.28	0.01	0.00	0.01	0.00	0.00	0.02	0.01	0.01	0.02	0.01	–	–	–	–
Total Current Assets	67	44	27	27	22	31	14	23	28	–	–	–	–	–	–	–	–	–	–	–
Other Long-Term Assets	0.72	0.82	0.82	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Total Assets	71	45	27	27	22	31	14	23	28	3.97	1.02	2.37	1.75	2.37	5.35	5.99	–	–	–	–
Accounts Payable	4.64	3.24	3.78	2.39	0.78	1.57	1.61	1.03	0.86	0.24	0.30	0.31	0.21	0.26	0.34	0.27	–	–	–	–
Accrued Expenses	5.64	3.43	3.75	2.22	0.88	0.78	0.66	0.61	0.62	0.13	0.09	0.13	0.13	0.42	0.05	0.20	–	–	–	–
Current Portion of Leases	–	0.00	0.02	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Deferred Revenue (Current)	0.25	0.25	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Total Current Liabilities	11	6.92	7.55	4.61	1.65	2.35	2.27	1.64	1.64	0.40	0.47	1.76	3.21	7.32	5.47	11	–	–	–	–
Long-Term Debt	–	–	–	–	5.00	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Long-Term Leases	–	–	0.00	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Operating Lease Liabilities	–	0.00	0.02	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Total Liabilities	35	51	38	30	6.64	2.35	2.27	1.64	1.64	0.40	0.47	1.76	3.21	7.32	5.47	11	–	–	–	–
Total Debt	–	–	–	–	5.00	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Common Stock	190	146	144	143	141	141	106	106	103	75	69	69	67	66	66	65	–	–	–	–
Additional Paid-In Capital	74	67	62	57	53	49	48	45	44	42	41	42	39	38	38	38	–	–	–	–
Retained Earnings	-229	-220	-219	-203	-179	-162	-144	-131	-121	-114	-112	-111	-109	–	–	–	–	–	–	–
Comprehensive Income & Other	1.24	1.24	1.24	1.24	1.24	1.24	1.24	1.24	1.24	1.24	1.24	1.24	1.24	1.24	1.24	1.24	–	–	–	–
Shareholders' Equity	35	-5.87	-12	-2.57	16	29	12	21	27	3.57	0.55	0.61	-1.46	-4.96	-0.12	-4.93	0.41	3.05	14	1.27
Total Equity	35	-5.87	-12	-2.57	16	29	12	21	27	3.57	0.55	0.61	-1.46	-4.96	-0.12	-4.93	0.41	3.05	14	1.27
Total Liabilities & Equity	71	45	27	27	22	31	14	23	28	3.97	1.02	2.37	1.75	2.37	5.35	5.99	–	–	–	–
Shares Outstanding(shares)	34	28	27	26	26	26	20	20	18	14	11	11	9.72	8.39	0.01	6.82	–	–	–	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: –
Operating margin: -1.9%
Net margin: -5.5%
Return on equity, FY2025: -65.8%

Financial strength

Current ratio: 5.85
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 332.8%

Valuation

P/E ratio: –
Price to sales: 6.32
Price to book: 8.82
Dividend yield: –